Amorfix and Ontario Genomics Institute announce partnership to accelerate development of blood test for Alzheimer's Disease
Amorfix Life Sciences Inc. and the Ontario genomics Institute (OGI) announced they are entering into a partnership to develop a blood test for Alzheimer's disease, EP-AD(TM), based upon Amorfix's patent-pending Epitope Protection technology. OGI will assist Amorfix in accelerating its program for diagnosis of neurodegenerative diseases drawing on OGI's portfolio of state-of-the-art genomics and proteomics facilities, research and pre-commercial development in Ontario.
Dr. Neil Cashman, Amorfix's CSO said, "Until now, it has been very difficult to detect aggregated misfolded proteins in blood where normal protein is prevalent. With our progress on the Epitope Protection platform, we are now in a position to finish our development of a test for Alzheimer's A-beta aggregates in blood."
Pursuant to a term sheet executed December 22, 2005, OGI has executed a subscription agreement to invest $100,000 in Amorfix to accelerate the EP-AD(TM) project. OGI will, upon closing, invest $50,000 receiving 100,000 common shares of AMF and 50,000 warrants to purchase shares for $.90 for a term of two years. Upon the achievement of a defined research milestone, OGI will invest $50,000 at market price and receive a one-half warrant for each share purchased to purchase a share at the then market price within 2 years. This transaction is subject to acceptance for filing by the TSX Venture exchange.
Most read news
Topics
Organizations
Other news from the department science
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New Head of Marketing Communications and PR at JULABO
New test improves diagnosis of allergies - Higher diagnostic accuracy than standard tests
HeartBeat.bio raises € 4.5 million in Pre-Series A financing - New funds to drive development of organoid screening platform for cardiac drug discovery
New computer vision system designed to analyse cells in microscopy videos
Musical sensor shows bad medicine plays false note - Inspired by a musical instrument, the simple sensor can be constructed from common materials and used to detect adulterated or counterfeit drugs
PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12
How can we fight blood cancer more effectively? - Several hundred different treatment combinations to be tested simultaneously outside the body
LGC announces plans to expand forensic services with new facilities to be created in Runcorn, Cheshire
Synthetic Production of Potential Pharmaceuticals Dramatically Simplified by Scripps Research Team - Findings Could Expand Interest in Natural Products by Making Production More Cost-Effective
Light-induced shape shifting of MXenes - Femtosecond light creates switchable nano-waves in MXenes and moves the materials’ atoms at a record-breaking speed
Brooks Instrument Joins Major Biotechnology Consortium Focused on Regenerative Drug Manufacturing - Brooks Instrument will contribute insights and precision fluid control technology to the Advanced Regenerative Manufacturing Institute’s BioFabUSA program